Legend Biotech Corporation (LEGN)
After hours:
| Previous Close | 43.09 |
| Open | 43.53 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 42.01 - 43.63 |
| 52 Week Range | 38.60 - 70.13 |
| Volume | |
| Avg. Volume | 953,160 |
| Market Cap | 7.9B |
| Beta (5Y Monthly) | 0.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.54 |
| Earnings Date | Nov 18, 2024 - Nov 22, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 83.14 |
Insider MonkeyIs Legend Biotech Corporation (LEGN) the Most Promising Biotech Stock According to Hedge Funds?
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going to take a look at where Legend Biotech Corporation (NASDAQ:LEGN) stands against the other promising biotech stocks. Biotechnology stocks are known for their high risk, making them some of the most volatile in the […]
GlobeNewswireLegend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
New 31,000 square-foot facility will enhance Legend’s leading cell therapy portfolio and expand Legend’s R&D capabilities as a global cell therapy leaderSOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), announced it is establishing a new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies. “This new facility underscores Legend’s commitment to
